Table 2. Ongoing trials for gastric cancer.
| Trial phase | Cancer type | Treatment arm | Control arm | Sponsor/country | Primary outcome | ECD |
|---|---|---|---|---|---|---|
| II | Gastric | NIPS + HIPEC + AC | N/A | Hospital General Universitario Gregorio Marañon, Spain | DFS | 2017 |
| II | Gastric | Laparoscopic HIPEC | N/A | M.D. Anderson Cancer Center, USA | OS | 2019 |
| III | Gastric* | D2 resection + HIPEC | N/A | Hospices Civils de Lyon, France | OS | 2021 |
*, locally advanced gastric cancer. No peritoneal carcinomatosis. ECD, estimated completion date; NIPS, neoadjuvant systemic plus simultaneous intraperitoneal and intravenous chemotherapy; HIPEC, hyperthermic intraperitoneal chemotherapy; AC, adjuvant chemotherapy; DFS, disease free survival; OS, overall survival.